|
 |
|
|
|
|
|
|
|
|
|
|
partnerships
|
|
|
|
|
OPPH is currently in partnership with three companies: CIS Pharma, BioCydex, and Laboratoires SERB. OPPH also continues to pursue negotiations with prospective partners, creating the possibility for new products that will increase the depth and breadth of our product pipeline.
CIS Pharma, a private Swiss company located near Basel, is a recognized leader in the formulation and production of complex molecules for ophthalmic applications. CIS Pharma has been delivering innovative technologies for over 50 years, with ophthalmology being its main area of expertise. OPPH has entered into a strategic alliance with CIS Pharma to develop ophthalmic products.
BioCydex is a private French biotechnology company with a proprietary platform based on novel third generation monosubstituted cyclodextrins. OPPH and BioCydex have a worldwide exclusive licensing agreement for applications of cyclodextrin technologies in ophthalmology.
 Laboratoires SERB, a French specialty pharmaceutical company with expertise in antidotes and ophthalmologic diagnostics, is collaborating with OPPH to develop a partnership strategy for two of its molecules, sodium fluoresceine and indocyanine green.
| | | | |
|
|
|
|